Jouni covered the numbers earlier in the slides. Maybe I'll give some more color here. So, sales were up 14.2%. In the second quarter, looking at the gross margin, it was very much in line with the top line growth. So, both the top line and gross margin grew for the full first six months and the second quarter, aligning with each other.
Also, the gross margin was at a similar level to last year. So there were actually very few surprises there on the margin side. We did have some write-offs, as Jouni mentioned. During the quarter, we wrote down all non-strategic capitalizations that we had in the balance sheet. Mostly related to vintage Vertica. And that was $730,000. So, looking at operating income. Operating profit, the adjusted numbers are a better line to look at if you want to understand the core business performance. Coincidentally, last year in the same quarter, we had $800,000 in one-time project costs that impacted the numbers back then. Both of these figures have been adjusted in the adjusted operating profit line. So $6 million for the second quarter and $5.540 million for Q2 of 2023, resulting in approximately 9% growth. And for the whole year, for the first six months. There's a small decline still in the adjusted EBITDA number. I'll go through the other numbers in more detail in the later slides. So basically a good quarter. Very much in line with what we and the market expected. So, as we said earlier, we are going into the year. Q1 and Q4 were challenging from a comparability point of view. And then, in Q2 and Q3, we noted the quarters wherein there was potential for better growth. Um, so basically, looking at the numbers, how they came in, it was very much according to our initial and internal thinking, also how we thought the year would be going. So, year to date, things are going as planned with FX-adjusted growth at 13.5%, as you already mentioned. It's also nice to see that the Q2 top line is coming back closer to the trend line. Q2 has often been below the trend line in earlier years as well. 2022 was an exceptional year where that was not the case. So, uh, exceptionally good year in 2022. Standing out here is also reflected in the graph. Um, so looking at the profitability, also with a bit of a longer tail, now going back from 5.1 million to 6 million in the second quarter. And basically, typically looking back at the earlier years, the second quarter has always been stronger than the first quarter for us. From a profit point of view. Last year was an exception in that regard. So you can see here also that last year, the Q2 was kind of soft from a performance point of view. This year, just as a reminder, the cost side for us, particularly personnel expenses, is expected to grow mainly due to very little bonus accruals included in the numbers for the 2023 performance. So hopefully this year we will deliver as we planned and have guided, so most likely those costs will go up. As mentioned earlier, we have budgeted between 1.5 to 2 million dollars for clinical trial costs this year, though it is still a bit open. How that's going to play out in the second half. There was very little in Q2, quite a bit in Q1. Towards the end of the year, we will likely incur some costs impacting our numbers due to clinical trials. Um, but those plans are still somewhat open, and we do not have full visibility yet into how that's going to play out in the coming months. Uh, cash flow. Excellent. Looking at last year, Q1 was positive at 300,000. Q2 was negative, actually. This year, we're above 11 million for the same two quarters. Um, there are basically a few reasons. Typically, in Q1, incentive payments for the entire company are distributed based on the previous year's performance. So that typically brings down the Q1 number. This year, there were significantly lower payments related to those. Um, also the working capital has been improved. In Q2, net income was higher than in the comparable period, playing into their advantage. Just a reminder, last year's Q2 cash flow was impacted by the Italian subsidiary's income tax payments. The tax system there is a bit different. We did make some payments related to the earlier years. These were not payments for 2023, but for 2022, which also affected the Q2 numbers last year. But overall, the results were very good, if not record-setting.
The first half had excellent cash flow. The balance sheet continues to get stronger over the last quarters. We're approaching a 75% equity ratio with net gearing below zero. We paid out the dividend. Based on the AGM on April 4th, a dividend of $0.38 was paid out. The dividend payout ratio was slightly above 50%. This is one of the reasons why the equity ratio has continued to grow. Regarding shareholders, there hasn't been much change here. William Demant Invest A/S bought some more shares.
Not a significant amount. However, foreign ownership has grown by 0.7 or 0.8% from the end of Q1. The first five companies or owners are in the same positions as in Q1, albeit in a slightly different order from 6 to 10. Ownership at these ranks is very similar, and only William Demant Invest A/S is a clear major shareholder. Then the ownership splits into much smaller pieces after that.
Our guidance remains unchanged. Revenue growth, with exchange rate adjustments, and net sales are estimated to grow by 5 to 10% from the previous year, while profitability, excluding non-recurring items, is estimated to remain at a good level. Great.